Athyrium Capital Management, LP - Q2 2024 holdings

$33.5 Million is the total value of Athyrium Capital Management, LP's 3 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 66.7% .

 Value Shares↓ Weighting
NewCOHERUS BIOSCIENCES INCnote 1.500% 4/1$22,229,85030,000,000
+100.0%
66.28%
 Biora Therapeutics Inc.$7,213,643
-40.0%
10,929,7620.0%21.51%
+30.2%
PBYI  PUMA BIOTECHNOLOGY INC$4,095,900
-38.5%
1,256,4110.0%12.21%
+33.5%
ExitOmeros Corpnote 5.250% 2/1$0-72,979,000
-100.0%
-74.33%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2024-08-08
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Amryt Pharma PLC10Q1 202346.3%
PUMA BIOTECHNOLOGY INC10Q2 202412.2%
Progenity Inc.9Q4 202269.2%
Omeros Corp9Q1 202474.3%
Progenity Inc.8Q3 202339.2%
RVL PHARMACEUTICALS PLC8Q3 202311.5%
Societal CDMO Inc.8Q4 20223.1%
CAREMAX INC7Q4 202227.5%
Omeros Corp7Q3 20239.9%
AEGERION PHARMACEUTICALS INC6Q1 201988.7%

View Athyrium Capital Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Athyrium Capital Management, LP Q2 2024 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
PROGENITY, INC.August 27, 20214,211,9772.7%

View Athyrium Capital Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
N-PX2024-08-30
13F-HR2024-08-08
13F-HR2024-05-16
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR/A2023-05-16
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14

View Athyrium Capital Management, LP's complete filings history.

Compare quarters

Export Athyrium Capital Management, LP's holdings